

# Scott L. Kaufman

Partner

212 660 3026

[skaufman@sullivanlaw.com](mailto:skaufman@sullivanlaw.com)



Scott co-leads Sullivan's Emerging Companies & Venture Capital Group. He represents entrepreneurs, technology and life science companies and investors, including family offices, in venture financings, M&A and other corporate transactions.

Scott's clients are in a number of areas including Digital Health, Digital Media, Web3, Blockchain/Cryptocurrency, Biotech/Life Sciences, Data Analytics and Software.

Scott is a trusted advisor and serves as outside general counsel to a number of his clients. He has significant experience advising Israeli and other International hi-tech companies in connection with their business transactions in the United States.

## Education

- Duke University School of Law (J.D., *with honors*)
- University of Michigan (B.A., *with distinction*)

## Bar & Court Admissions

- New York

## Awards & Honors

- Recommended by *The Legal 500 U.S.* (2019-2026)
- New York *Super Lawyers* (2023-2026)

## Matters

---

- Represented Truliant Consulting, a leading pharmacovigilance, risk management, and regulatory compliance advisory firm, in connection with its acquisition by ELIQUENT Life Sciences
- Represented KUDO, the cloud-based video conferencing platform with real-time multilingual interpretation in 100+ languages and 147 sign languages, on its

## Capabilities

- Capital Markets
- Commercial & Technology Transactions
- Corporate
- Emerging Companies & Venture Capital
- Finland/Nordic Practice
- Fintech & Blockchain
- Global Capital Markets
- Hi-Tech
- Israel/Middle East
- Life Sciences
- Life Sciences Industry
- Mergers & Acquisitions
- Private Equity
- Private Investment Funds & Institutional Investors
- Venture Capital

\$21M Series A Preferred Stock financing

- Represented Somatix, a digital health company focused on remote patient monitoring, in connection with its Series A financing, convertible notes offering and day-to-day matters
- Represented Rescue Hearing, a gene therapy company, in connection with its license to Myrtelle Inc. to develop a novel gene therapy for hearing loss
- Represented DarioHealth (Nasdaq: DRIO), a digital therapeutics company, in connection with its \$30 million acquisition of PsylInnovations, Inc., dba wayForward, a behavioral health digital platform
- Represented Clear Genetics, a software company focused on integrating genetics into routine patient care, in connection with its \$50 million acquisition by Invitae Corporation (NYSE: NVTX)
- Represented 97212 Studio, an accelerator focused on supporting Israeli tech companies expanding to the United States, in connection with its formation and financing
- Represented family offices in connection with their investments in venture funds, start-up companies and real estate
- Represented many early-stage companies in connection with their formation, initial stockholder arrangements and seed financings